Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Cosmos Health (COSM) EBITDA (2016 - 2025)

Cosmos Health (COSM) has disclosed EBITDA for 13 consecutive years, with -$5.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 33.19% year-over-year to -$5.1 million, compared with a TTM value of -$17.4 million through Sep 2025, up 46.78%, and an annual FY2024 reading of -$24.1 million, up 3.9% over the prior year.
  • EBITDA was -$5.1 million for Q3 2025 at Cosmos Health, down from -$1.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $213171.0 in Q1 2025 and bottomed at -$36.6 million in Q4 2022.
  • Average EBITDA over 5 years is -$6.6 million, with a median of -$2.8 million recorded in 2024.
  • The sharpest move saw EBITDA plummeted 8818.8% in 2022, then surged 108.64% in 2025.
  • Year by year, EBITDA stood at -$410611.0 in 2021, then tumbled by 8818.8% to -$36.6 million in 2022, then soared by 45.95% to -$19.8 million in 2023, then soared by 43.27% to -$11.2 million in 2024, then skyrocketed by 54.61% to -$5.1 million in 2025.
  • Business Quant data shows EBITDA for COSM at -$5.1 million in Q3 2025, -$1.3 million in Q2 2025, and $213171.0 in Q1 2025.